Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Author index

Page Path
HOME > Browse articles > Author index
Search
Yutaka Yano 1 Article
IBD
Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
Akihiro Koga, Toshiyuki Matsui, Noritaka Takatsu, Yasumichi Takada, Masahiro Kishi, Yutaka Yano, Takahiro Beppu, Yoichiro Ono, Kazeo Ninomiya, Fumihito Hirai, Takashi Nagahama, Takashi Hisabe, Yasuhiro Takaki, Kenshi Yao, Hirotsugu Imaeda, Akira Andoh
Intest Res 2018;16(2):223-232.   Published online April 30, 2018
DOI: https://doi.org/10.5217/ir.2018.16.2.223
AbstractAbstract PDFSupplementary MaterialPubReaderePub
<b>Background/Aims</b><br/>

Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether TLI or ATI better correlates with LOR (Study 1), and whether TLI could become a predictor of mucosal healing (MH) (Study 2).

Methods

Study 1 was conducted in 108 patients, including those with LOR and remission to compare ATI and TLI in discriminating the 2 conditions based on receiver operating characteristic (ROC) curve analyses. Study 2 involved 35 patients who were evaluated endoscopically.

Results

In Study 1, there were no differences between the 2 assays in ROC curve analyses; the TLI cutoff value for LOR was 2.6 µg/mL (sensitivity, 70.9%; specificity, 79.2%), and the ATI cutoff value was 4.9 µg/mL (sensitivity, 65.5%; specificity, 67.9%). The AUROC (area under the ROC curve) of TLI was greater than that of ATI. AUROC was useful for discriminating between the 2 conditions. In Study 2, the TLI was significantly higher in the colonic MH group than in the non-MH group (2.7 µg/mL vs. 0.5 µg/mL, P=0.032).

Conclusions

TLI is better than ATI for clinically diagnosing LOR, and a correlation was observed between TLI and colonic MH.

Citations

Citations to this article as recorded by  
  • Is infliximab therapy currently relevant in patients with inflammatory bowel diseases? (review)
    T. L. Alexandrov, B. A. Vykova
    Koloproktologia.2024; 23(2): 173.     CrossRef
  • Mucosal and Transmural Healing and Long-term Outcomes in Crohn’s Disease
    Bruce E Sands, Silvio Danese, J Casey Chapman, Khushboo Gurjar, Stacy Grieve, Deepika Thakur, Jenny Griffith, Namita Joshi, Kristina Kligys, Axel Dignass
    Inflammatory Bowel Diseases.2024;[Epub]     CrossRef
  • Expression of inflammatory mediators in biofilm samples and clinical association in inflammatory bowel disease patients—a preliminary study
    Mayte Buchbender, Jakob Fehlhofer, Peter Proff, Tobias Möst, Jutta Ries, Matthias Hannig, Markus F. Neurath, Madline Gund, Raja Atreya, Marco Kesting
    Clinical Oral Investigations.2022; 26(2): 1217.     CrossRef
  • Microbiota and Drug Response in Inflammatory Bowel Disease
    Martina Franzin, Katja Stefančič, Marianna Lucafò, Giuliana Decorti, Gabriele Stocco
    Pathogens.2021; 10(2): 211.     CrossRef
  • Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease
    Eran Zittan, A. Hillary Steinhart, Pavel Goldstein, Raquel Milgrom, Ian M. Gralnek, Mark S. Silverberg
    Clinical and Translational Gastroenterology.2021; 12(10): e00401.     CrossRef
  • Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients
    So Yoon Choi, Young Ok Choi, Yon Ho Choe, Ben Kang
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases
    Ana B. Grinman, Maria das Graças C. de Souza, Eliete Bouskela, Ana Teresa P. Carvalho, Heitor S. P. de Souza
    Medicine.2020; 99(10): e19359.     CrossRef
  • Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle
    Gyeol Seong, Namil Kim, Je-Gun Joung, Eun Ran Kim, Dong Kyung Chang, Jongsik Chun, Sung Noh Hong, Young-Ho Kim
    Microorganisms.2020; 8(6): 874.     CrossRef
  • Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events
    Mitchell R. K. L. Lie, Emma Paulides, C. Janneke van der Woude
    International Journal of Colorectal Disease.2020; 35(8): 1489.     CrossRef
  • Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn’s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment
    Ting Feng, Baili Chen, Bella Ungar, Yun Qiu, Shenghong Zhang, Jinshen He, Sinan Lin, Yao He, Zhirong Zeng, Shomron Ben-Horin, Minhu Chen, Ren Mao
    Inflammatory Bowel Diseases.2019; 25(11): 1813.     CrossRef
  • Mucosal healing in inflammatory bowel disease: Expanding horizon
    Jimil Shah, Manik Lal Thakur, Usha Dutta
    Indian Journal of Gastroenterology.2019; 38(2): 98.     CrossRef
  • 6,802 View
  • 75 Download
  • 10 Web of Science
  • 11 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP